4D Molecular Therapeutics (FDMT) Revenue (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Revenue of $3.0 million for Q1 2026, up 21664.29% year-over-year from N/an in Q1 2025, and down 96.42% quarter-over-quarter from $85.1 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Revenue (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Revenue for 7 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 21664.29% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $88.2 million (up 383560.87% YoY), while the FY2025 annual figure was $85.2 million, up 230194.59% from the prior year.
- Revenue retreated to $3.0 million in Q1 2026 per FDMT's latest filing, from $85.1 million in the prior quarter.
- Across five years, Revenue topped out at $85.1 million in Q4 2025 and bottomed at -$19000.0 in Q4 2023.
- Historically, Revenue has averaged $6.6 million across 5 years, with a median of $162000.0 in 2022.
- Annual changes were most pronounced in 2023 — Revenue tumbled 101.52% — and 2025, when it jumped 8508900.0%.
- 4D Molecular Therapeutics' Revenue stood at $1.2 million in 2022, then slumped by 101.52% to -$19000.0 in 2023, then jumped by 105.26% to $1000.0 in 2024, then surged by 8508900.0% to $85.1 million in 2025, then sank by 96.42% to $3.0 million in 2026.
- Business Quant data shows FDMT's Revenue at $3.0 million in Q1 2026, $85.1 million in Q4 2025, and $90000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.78 Mn |
| Mar 31, 2026 | 3.05 Mn |
| Dec 31, 2025 | 85.09 Mn |
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 15,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | -19,000.00 |
| Sep 30, 2023 | 20.20 Mn |
| Jun 30, 2023 | 239,000.00 |
| Mar 31, 2023 | 298,000.00 |
| Dec 31, 2022 | 1.25 Mn |
| Sep 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 162,000.00 |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 92,000.00 |
| Sep 30, 2021 | 1.37 Mn |